Phase
Condition
Dermatitis, Atopic
Atopic Dermatitis
Allergy
Treatment
ACT02
Placebo
ACT01
Clinical Study ID
Ages 18-55 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Phototype: I to V;
Subjects with atopic skin (with at least 1 visible xerosis + inflammation on thebody);
Subjects with a history background of asthma, rhinitis and/or allergicconjunctivitis;
Subjects with SCORAD between 8 and 30 (at least 50% or more having around 8-10);
Subjects with BMI between 20 and 30 kg/m2 (limits included);
Subjects who have not recently participated in another similar study;
Willingness to take supplements for the duration of the study;
Willingness not to use products likely to interfere with the test product (collagen,hyaluronic acid, anti-stress products);
Willingness not to change lifestyle habits;
Willingness to avoid intensive UV exposure;
Use of contraception that should not be modified during the study.
Healthy subject;
Mentally healthy subject according to Investigator's opinion;
Subject having given his/her free informed, written consent;
Subject agrees to taking photograph and then use the image after itspseudonymization;
Subject willing to adhere to the protocol and study procedures;
Subject able to understand the study;
Subject available to attend the study visits.
Exclusion
Exclusion Criteria:
Pregnant or nursing woman or woman planning to get pregnant during the study;
Cutaneous marks on the experimental areas, which could interfere with the assessmentof skin reactions;
Subjects who have participated in the last 3 months or are currently participatingin another clinical trial that may interfere with the evaluation of the primaryendpoint (endpoint AD);
Current administration of antibiotics;
Known history of chronic disease such as congenital heart disease, liver or kidneydisease, or immune deficiency;
Topical treatment with immunomodulators (tacrolimus or pimecrolimus) in the threemonths prior to registration;
Application of moisturizing products on the experimental area the day of theinclusion of the study;
Acute or chronic infectious diseases;
Not meet inclusion criteria;
Those undergoing aesthetic medicine (fillers, hyaluronic acid injections, botox)that could interference in the experimental area;
Subjects suffering Alimentary/Eating disorders (i.e. bulimia, psychogenic eatingdisorders, etc.)
Subjects having frequent stomach burn;
Allergy or intolerance to any ingredient of the experimental food supplement;
Subjects with diabetes mellitus;
Fish and/or iodine allergy;
Intestinal conditions or disorders (Crohn's disease, colitis, irritable bowelsyndrome, intestinal malabsorption...)
Recent change, forecast of initiation of an hormonal treatment or change of theusual hormonal treatment during the study or 3 months before the starting of thestudy;
Subject having undergone a surgery under general anesthesia within the previousmonth;
Exposure in UVA ray sunbed during the 3 months before the start of the study on theexperimental area or during the study;
Subjects protected by the law;
Subject employed by EUROFINS PRODUCT TESTING, COSMETICS & PERSONAL CARE SPAIN,S.L.U.
Study Design
Study Description
Connect with a study center
Eurofins
Barcelona, 08013
SpainSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.